| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
63,940,000 |
| Market
Cap: |
2.58(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$21.33 - $40.39 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Chinook Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing precision medicines for kidney diseases. Co.'s pipeline is focused on kidney diseases with clinical pathways. Co.'s lead clinical program is atrasentan, an endothelin A receptor antagonist. Co.'s second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in development for patients with IgA nephropathy. Co. developing CHK-336 for the treatment of primary hyperoxaluria as well as secondary hyperoxaluria and idiopathic kidney stone formation. Co. is also conducting research programs in several other rare, severe chronic kidney diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
585,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$8,257,342 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
2,323 |
873,253 |
| Total Sell Value |
$0 |
$0 |
$72,498 |
$19,325,721 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
25 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  King Andrew James |
Chief Scientific Officer |
• – – |
2022-07-11 |
4 |
AS |
$18.09 |
$90,468 |
D/D |
(5,000) |
5,897 |
|
19% |
|
| King Andrew James |
Chief Scientific Officer |
• – – |
2022-07-11 |
4 |
OE |
$0.35 |
$1,750 |
D/D |
5,000 |
10,897 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2022-05-27 |
4 |
B |
$14.00 |
$7,980,000 |
I/I |
570,000 |
5,161,888 |
2.1 |
26% |
|
| Dobmeier Eric |
President, CEO |
• • – |
2022-05-25 |
4 |
B |
$13.03 |
$65,148 |
D/D |
5,000 |
205,880 |
2.81 |
47% |
|
| King Andrew James |
Chief Scientific Officer |
• – – |
2022-04-11 |
4 |
AS |
$15.36 |
$76,812 |
D/D |
(5,000) |
5,897 |
|
44% |
|
| King Andrew James |
Chief Scientific Officer |
• – – |
2022-04-11 |
4 |
OE |
$0.35 |
$1,750 |
D/D |
5,000 |
10,897 |
|
- |
|
| Versant Voyageurs I Parallel, L.p. |
10% Owner |
– – • |
2022-04-04 |
4 |
AS |
$0.00 |
$0 |
I/I |
(25,920) |
0 |
|
19% |
|
| Versant Voyageurs I Parallel, L.p. |
10% Owner |
– – • |
2022-04-04 |
4 |
A |
$0.00 |
$0 |
I/I |
25,920 |
11,726 |
|
- |
|
| Versant Voyageurs I Parallel, L.p. |
10% Owner |
– – • |
2022-04-04 |
4 |
AS |
$0.00 |
$0 |
D/D |
(709,953) |
2,913,070 |
|
19% |
|
| Jerel Davis |
Director |
– • • |
2022-04-04 |
4 |
AS |
$0.00 |
$0 |
I/I |
(735,873) |
0 |
|
19% |
|
| Jerel Davis |
Director |
– • • |
2022-04-04 |
4 |
A |
$0.00 |
$0 |
I/I |
25,920 |
11,726 |
|
- |
|
| Jerel Davis |
Director |
– • • |
2022-04-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,468 |
732,938 |
|
- |
|
| King Andrew James |
Chief Scientific Officer |
• – – |
2022-02-18 |
4 |
AS |
$13.00 |
$32,500 |
D/D |
(2,500) |
5,897 |
|
34% |
|
| Glicklich Alan |
Chief Medical Officer |
• – – |
2022-02-11 |
4 |
S |
$12.74 |
$30,464 |
D/D |
(2,391) |
7,891 |
|
-46% |
|
| Frohlich Tom |
Chief Operating Officer |
• – – |
2022-02-11 |
4 |
S |
$12.74 |
$47,587 |
D/D |
(3,735) |
137,685 |
|
-46% |
|
| Bjerkholt Eric |
Chief Financial Officer |
• – – |
2022-02-11 |
4 |
S |
$12.74 |
$11,403 |
D/D |
(895) |
22,203 |
|
-46% |
|
| King Andrew James |
Chief Scientific Officer |
• – – |
2022-02-11 |
4 |
S |
$12.74 |
$31,827 |
D/D |
(2,498) |
8,397 |
|
-46% |
|
| Glicklich Alan |
Chief Medical Officer |
• – – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,668 |
10,282 |
|
- |
|
| Dobmeier Eric |
President, CEO |
• • – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,247 |
200,880 |
|
- |
|
| Frohlich Tom |
Chief Operating Officer |
• – – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,801 |
141,420 |
|
- |
|
| Bjerkholt Eric |
Chief Financial Officer |
• – – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,434 |
23,098 |
|
- |
|
| King Andrew James |
Chief Scientific Officer |
• – – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,801 |
10,895 |
|
- |
|
| King Andrew James |
Chief Scientific Officer |
• – – |
2022-02-10 |
4 |
AS |
$13.31 |
$33,275 |
D/D |
(2,500) |
4,094 |
|
42% |
|
| King Andrew James |
Chief Scientific Officer |
• – – |
2022-02-10 |
4 |
OE |
$0.35 |
$875 |
D/D |
2,500 |
6,594 |
|
- |
|
| Versant Voyageurs I Parallel, L.p. |
10% Owner |
– – • |
2022-01-03 |
4 |
AS |
$16.00 |
$6,400,080 |
I/I |
(400,000) |
552,149 |
|
-21% |
|
475 Records found
|
|
Page 4 of 19 |
|
|
